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ABSTRACT Osteoblasts express calcium channels that
are thought to be involved in the transduction of extracellular
signals regulating bone metabolism. The molecular identity of
the pore-forming subunit (a1) of L-type calcium channel(s)
was determined in rat osteosarcoma UMR-106 cells, which
express an osteoblast phenotype. A homology-based reverse
transcriptase-polymerase chain reaction cloning strategy was
employed that used primers spanning the fourth domain.
Three types of cDNAs were isolated, corresponding to the ails
(skeletal), alc (cardiac), and aiD (neuroendocrine) isoforms.
In the transmembrane segment IVS3 and the extracellular
loop formed by the IVS3-S4 linker, a single pattern of mRNA
splicing was found that occurs in all three types of calcium
channel transcripts. Northern blot analysis revealed an 8.6-kb
mRNA that hybridized to the calc probe and 4.8- and 11.7-kb
mRNAs that hybridized to the als and aiD probes. Antisense
oligonucleotides directed to the calcium channel aID transcript,
but not those directed to als or aic transcripts, inhibited the rise
of intracellular calcium induced by parathyroid hormone. How-
ever, aIlD antisense oligonucleotides had no effect on the accu-
mulation of cAMP induced by parathyroid hormone. When
L-type calcium channels were activated with Bay K 8644, anti-
sense oligonucleotides to each of the three isoforms partially
inhibited the rise of intracellular calcium. The present results
provide evidence for the expression of three distinct calcium
channel a,-subunit isoforms in an osteoblast-like cell line. We
conclude that the ailD isoform is selectively activated by para-
thyroid hormone.
Voltage-gated calcium (Ca2+) channels were first described in
excitable cells and are generally classified as L, N, P, and T type
(1). L-type Ca2+ channels are defined by their high-voltage-
dependent activation and by their sensitivity to organic Ca2+
channel blockers, including dihydropyridines (2). Ca2+ chan-
nels are multimeric complexes whose properties are largely
conferred by the pore-forming 'a1 subunit, which contains four
homologous domains, each with six putative transmembrane
regions (S1-S6). At least six Ca2+ channel a, subunit genes
have been identified including three L-type isoforms (3).
Additional diversity of Ca2+ channel structure is generated by
alternative splicing, which gives rise to multiple transcripts
from each gene.
Osteoblasts play a central role in the regulation of bone
metabolism because they are responsible for bone formation
and modulate bone resorption by osteoclasts. Parathyroid
hormone (PTH), the principal hormone regulating serum Ca2+,
causes a rapid Ca2+ influx into osteoblasts through plasma
membrane Ca2+ channels (4, 5). The Ca2+ signals generated are
likely to be involved in the induction of intracellular responses
that regulate bone turnover (6). The pharmacological and kinetic
characteristics of osteoblast Ca2+ channels resemble those of
L-type voltage-gated Ca2+ channels expressed in excitable cells
(7-12).
The purpose of the present study was to determine the
molecular identity of L-type Ca2+ channels expressed in UMR-
106 osteoblast-like cells and to examine their regulation by PTH.
Three types of cDNA clones were isolated corresponding to all
three isoforms of L-type voltage-gated Ca2+ channels that have
been described in excitable cells.§ A rare pattern of alter-
native splicing was found to occur in all three types of
transcripts. Antisense oligonucleotides (ODNs) were used to
demonstrate that PTH selectively activates the a1D isoform.
Some of these results have been presented (13).
EXPERIMENTAL PROCEDURES
cDNA Synthesis and PCR. UMR-106 cells (14) were ob-
tained from American Type Culture Collection and were
cultured in Dulbecco's modified Eagle's medium/Ham's F-12
medium (Sigma) containing 10% (vol/vol) fetal bovine serum
(Sigma). Poly(A)+ RNA was isolated from cultured cells by
using the FastTrack mRNA isolation kit (Invitrogen). Reverse
transcription and cDNA amplification were carried out with
the GeneAmp RNA PCR kit (Perkin-Elmer/Cetus) on 250 ng
of poly(A)+ RNA. Thirty cycles of PCR were performed: 60
s at 94°C, 60 s at 60°C, and then 120 s plus 2 s per cycle at 72°C.
PCR primer ODNs (Macromolecular Resources, Fort Collins,
CO) were designed to amplify essentially the entire fourth
domain by using regions that are highly conserved between the
a, subunit of L-type Ca2+ channels in published sequences: als
(rabbit skeletal muscle isoform) (15), alc (rat cardiac muscle
isoform) (16), and alD (rat neuroendocrine isoform) (17). The
upstream primer was 5'-GCCGGATCCATCGTCACCTTC-
CAGGAGCA-3', and the downstream primer was 5'-ATG-
GAATTCGCCACRAAGAGGTTGATGAT-3' (R = A or
G). An additional downstream primer, 5'-CCCGAATTCAK-
MGTGTTGAGCATGATGAG-3' (K = T or G; M = A or C),
was designed from sequence in the IVS1 segment (residues
167-195) of the UMR-106 ROB1 and ROB3 rat osteoblast
clones to be used with the upstream primer to amplify only the
5' end of those clones. BamHI or EcoRI restriction sites
(underlined) were included near the 5' ends of the primers to
facilitate directional subcloning.
Cloning and Sequencing PCR Products. The PCR products
were directionally cloned into the pBluescript KS- vector
(Stratagene). For sequencing, 5 ,ug of plasmid DNA was
denatured in 200 mM NaOH/0.2 mM EDTA for 30 min at
37°C, neutralized, and precipitated in ethanol. Sequencing was
performed by the dideoxynucleotide chain-termination
method with the Sequenase II kit (United States Biochemical).
The products were separated by electrophoresis on 8.0%
polyacrylamide gels (Gel-Mix 8, GIBCO/BRL). The final
Abbreviations: [Ca2+]i, intracellular calcium activity; ODNs, oligode-
oxynucleotides; PTH, parathyroid hormone.
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§The sequences reported in this paper have been deposited in the
GenBank data base (accession nos. U31772, U31815, and U31816).
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sequences were determined from both strands of the cDNA.
Sequence analysis was performed with on-line software from
the Genetics Computer Group (Madison, WI).
Northern Blot Analysis. Poly(A)+ RNA was electropho-
resed on a 0.75% agarose/formaldehyde denaturing gel and
electrophoretically transferred to GeneScreenPlus nylon mem-
brane (DuPont/NEN). The membranes were UV-crosslinked
and baked for 2 h at 80°C under vacuum. Prehybridization was
carried out in 0.25 M sodium phosphate/pH 7.2/0.25 M
NaCl/1 mM EDTA/50% (vol/vol) formamide/6% (wt/vol)
SDS at 55°C for 1 h. 32P-labeled RNA probes were synthesized
by using [c-32P]UTP (Amersham), linearized cDNA templates
and the Riboprobe Gemini System (Promega). After hybrid-
ization with RNA probes, 2 x 106 cpm/ml, the membranes
were washed and incubated with RNase A (1 jig/ml) for 15 min
at room temperature. Final high-stringency washes were in
0.04 M sodium phosphate, pH 7.2/1% SDS/1 mM EDTA at
650C.
Antisense Analysis. ODNs were introduced into UMR-106
cells during permeabilization with streptolysin 0 (GIBCO/
BRL) as described (18), with the following modifications. Cells
in suspension were incubated with streptolysin 0 (20 units/ml)
for 10 min at 37°C in the presence of 100 ,tM ODNs (sense or
antisense). Control cells were permeabilized in the absence of
ODNs. Cells were then washed and plated onto glass cover-
slips. After 18-24 h, intracellular calcium activity ([Ca2+]i) was
measured in single cells loaded with fura-2 (Molecular Probes)
as described (19). Antisense ODNs were designed from re-
gions of sequences that are divergent between the three Ca2+
channel isoforms to be highly specific: als, 5'-TTCCCG-
TAGCTGCAGGCCAG-3'; aic, 5'-CCTTCCGTGCTGTT-
GCTGGGCTCA-3'; aID, 5 '-ATCTGGTTGTTATCTCT-
CAT-3'. The dose ofODNs used (100 ,tM) and amount of time
after ODN treatment (18-24 h) before assaying for functional
inhibition of Ca2+ channel activity have been found to be
maximally inhibitory for the aic Ca2+ channel protein (18).
Measurement of cAMP. UMR-106 cells in suspension were
incubated for 15 min at 37°C in the presence or absence of 1
x 10-8 M bovine PTH-(1-84) prior to the addition of ice-cold
0.132 M trichloroacetic acid. The supernatant was extracted
with ether, dried, and used for the measurement of cAMP with
a kit from Diagnostic Products (Los Angeles).
Statistical Analysis. Comparisons between control and ex-
perimental treatment groups were evaluated by analysis of
variance (ANOVA) and post hoc analysis of multiple com-
parisons using the Bonferroni method (INSTAT; Graph-Pad
Software, San Diego). Values are the mean ± SEM; n, number
of experiments. P c 0.05 was assumed to be significant.
RESULTS
Homology-based reverse transcriptase-PCR was used to iden-
tify transcripts for L-type Ca2+ channels in UMR-106 cells.
Three types of cDNA clones were isolated, corresponding to
all three of the known L-type Ca2+ channel genes. The als
isoform (ROB1), 844 bp, is 91% identical at the nucleotide
level and 97% identical at the amino acid level to the rabbit
skeletal muscle als gene (15). In addition, there is a 57-bp
deletion (19 amino acids) in the S3-S4 linker region (Fig. 1).
The alc isoform (ROB2), 850 bp, is identical to the rat brain
rbC-I transcript (16), except for a 33-bp (11 amino acids)
deletion (Fig. 1) in the S3-S4 linker. Finally, the aiD isoform
(ROB3), 844 bp, is identical to the corresponding rat brain
transcript (17) except for two 1-bp changes, one of which
results in a conservative amino acid change, and a 45-bp (15
amino acid) deletion in the S3-S4 linker (Fig. 1). Partial
sequencing of four additional als clones and five alD clones
indicated that they all had the same pattern of alternative
splicing.
ROB1 RZZ=FLIVIGSIIDILSEID ................... SDPDEARISSAFFRLFRVMRLILLSRA
r1111111111 11 1111M 11 11 1 1
als1S N=VFLIrLVIGSI I WILSEIDIELASSG3GLYG!CNPDESARISSAFFLIRVMRGIS SRA
RDB2 ? NVFDELIVIGSIIWIILSEIN ................... SAEPJSPdSITFF VM RLVKLLSRG
1W11 1111111'1 11111 111111111111111111M M1!II 11
aic PNVFDFLWVIGSIIVILSENPAEHIaCSPSM 1L........ SAEENSRISITFEVMRLVKLLSRG
ROB3 EFDSLIVIGSISIUALSEAD ......... ..........NSEE SITFRLFRVMRLVKLSRG
I11111111111111111111 FIli IFF11111111FF1111 II I
aID ANNFDSLIVIGSIIDEALSEADPSDSENIPL=PATP. NSEESNRISITFF VMRLVKLLSRG
IVS3 TV124
FIG. 1. Comparison of the deduced amino acid sequences of the
UMR-106 clones with their corresponding calcium channel ai subunit
isoforms in the region where alternative splicing generates a deletion.
Comparisons: ROBI to the rabbit skeletal muscle als transcript (15);
ROB2 to the rat brain aic transcript (16); ROB3 to the rat brain aiD
transcript (17).
Northern blot analysis was used to detect expression of
mRNA transcripts corresponding to the UMR-106 Ca2+ chan-
nel clones (Fig. 2). Three sizes of mRNAs of approximately
11.7,8.6, and 4.8 kb were detected. The ROB2 clone hybridized
predominantly to the 8.6-kb mRNA, which is the expected size
for an aic isoform transcript (16, 20, 21). However, a larger 12-
to 15-kb transcript detected in other tissues (16, 20, 21),
including cardiac muscle, aorta, and brain, was not seen. The
ROB1 and the ROB3 clones hybridized to both the 4.8-kb
(major) and 11.7-kb (minor) mRNAs. The size of the 11.7-kb
transcript is similar to that reported (11.0 kb) for a human aID
isoform isolated from pancreatic 13 cells (22). Interestingly,
hybridization of the ROBM clone to a 6.5-kb band, such as that
seen in adult skeletal muscle (23), was not detected. However,
the shorter transcript (4.8 kb) is similar in size to the predom-
inant transcript reported in newborn skeletal muscle (24) and
in kidney (25). Very high-stringency washing was used during
Northern blot analysis to maximize the specificity of hybrid-
ization. Nevertheless, it is possible that the high degree of
sequence identity (-76%) of the three Ca2+ channel isoforms
in the region cloned may be responsible for some cross-
hybridization. In particular, the faint band at 4.8 kb detected
by the ROB2 clone may be due to cross-hybridization by virtue
of the relatively high abundance of those transcripts. In
addition, the 8.6-kb band detected by ROB3 is likely to
represent cross-hybridization since it was not labeled when a
shorter ROB3 probe was used (data not shown).
The truncated (4.5 kb) transcript described in newborn
muscle is generated by an internal deletion between IIS2 and
IVS2 giving rise to an isoform with only two homologous
domains (24). Northern blot analysis was used to examine
whether a similar deletion is responsible for the shorter







FIG. 2. Autoradiogram of a Northern blot of RNA hybridized to
UMR-106 calcium channel a,-subunit RNA probes. RNA probes were
hybridized to UMR-106 poly(A)+ RNA at 10 jig per lane for ROBI-
ROB3 probes or at 1 jig per lane for the actin probe. Autoradiography
was for 67 h (ROBs) or 6 h (actin). An RNA ladder (GIBCO/BRL)
was used for size markers (in kilobases).
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transcripts (4.8 kb) detected in UMR-106 cells with ROB1 and
ROB3 probes. A downstream primer (DP-3) was designed
from sequence in the IVS1 domain of the ROB1 and ROB3
cDNAs (corresponding to residues 167-195). This primer was
used along with the upstream primer from IIIS6 to generate
truncated cDNAs (225 bp) from ROB1 and ROB3, which
contain only the IIIS6-IVS1 linker and a portion of IVS1.
These cDNAs should not hybridize to the 4.8-kb mRNA from
UMR-106 cells if it is formed by an internal deletion between
IIS2 and IVS2. However, Northern blot analyses with either of
the ROB1 or ROB3 truncated cDNAs as probes and with the
full-length probes gave identical hybridization patterns (data
not shown). These results indicate that the 4.8-kb mRNAs
from UMR-106 cells are not formed by the same type of
internal deletion reported for the 4.5-kb mRNA from newborn
muscle.
Antisense analysis was used to examine which of the three
L-type Ca2+ channel al subunit isoforms is activated by PTH
in UMR-106 cells. In control cells that were not treated with
ODNs, PTH treatment caused [Ca2+]i to rise rapidly to a new
plateau (Fig. 3 and Table 1). However, in cells that had been
treated with antisense ODNs to the Ca2+ channel alD isoform,
the PTH-induced rise of [Ca2+l] was significantly reduced to 36
+ 4% of the increase seen in control cells. Treatment of cells
with aiD sense ODNs or with sense or antisense ODNs to the
als or ai-c isoforms did not alter the magnitude of the
PTH-induced rise of [Ca2+]j relative to control cells (Table 1).
Notably, basal [Ca2+]i was not significantly changed by treat-
ment of cells with any of the ODNs (data not shown). These
results indicate that treatment of UMR-106 cells with PTH
causes Ca2+ uptake through the selective activation of the
Ca2+ channel alD isoform.
Antisense ODNs directed to the alD Ca2+ channel mRNA
transcript are thought to reduce PTH-induced Ca2+ uptake by
specifically inhibiting the expression of the aiD Ca2+ channel
protein. To rule out a nonspecific effect of alD antisense
ODNs on the ability of UMR-106 cells to respond to PTH,
increases ofcAMP stimulated by PTH were measured (n = 3).
In control cells, cAMP production increased 35-fold from a
basal level of 10.7 ± 1.1 pmol/mg of protein in the absence of
PTH to 375 ± 77 pmol/mg of protein in the presence of PTH.
Neither basal nor PTH-stimulated cAMP formation was al-
tered by treatment of the cells with alD sense (basal, 10.9 + 1.0;
+PTH, 356 ± 70 pmol/mg of protein) or antisense ODNs
(basal, 10.8 ± 0.7; +PTH, 383 ± 33 pmol/mg of protein).
Thus, aiD antisense ODNs specifically inhibit Ca2+ uptake, but
not the formation of cAMP, induced by PTH.
Treatment with antisense ODNs to the aiD isoform only
partially inhibited the PTH-induced rise of [Ca2+]1, suggesting
that Ca2+ release from intracellular stores contributed to the
rise of [Ca2+]i. To examine this possibility, the PTH-induced
time, min
FIG. 3. Effect Of aiD (ROB3) antisense ODNs on the PTH-
induced rise of intracellular calcium. Representative traces of [Ca2+]
are shown for single cells in which basal [Ca2+]i was measured for 2 min
followed by exposure to 10-8 M PTH for 5 min.
Table 1. Summary of the effect of calcium channel ODNs on the
PTH-induced rise of [Ca2+]i
Treatment A[Ca2+], % control n
Control 100 ± 6 9
als antisense 103 ± 9 6
als sense 99 ± 18 3
aic antisense 102 ± 11 4
aic sense 82 ± 8 3
alD antisense 36 ± 4*t 9
alD sense 118 ± 16 6
A[Ca2+]1, the difference between resting and stimulated level of
[Ca2+]i after 10-8 M PTH treatment. In control cells, the basal level
of [Ca2+]j was 119 ± 4 nM and the PTH-stimulated level was 243 ±
21 nM. The results are presented as the percent of the A[Ca2+]I
obtained with control cells in the same set of experiments. *, P < 0.01,
alD antisense vs. control; t, P < 0.001, alD antisense vs. alD sense.
rise [Ca2+1] was measured in the absence of extracellular Ca2+
or the presence of nifedipine, an L-type Ca2+ channel antag-
onist. In the absence of extracellular Ca2+, the PTH-induced
rise [Ca2+], was 57 + 4% (n = 4) of the control value obtained
in the presence of extracellular Ca2+. Thus, a portion of the
PTH-induced rise of [Ca2+]i is due to release from intracel-
lular stores. The effect of nifedipine on the PTH-induced rise
of [Ca2 ]i was assessed in control cells and cells treated with
aiD ODNs (Fig. 4). Nifedipine significantly reduced the mag-
nitude of the PTH-induced rise of [Ca2+]1 in control and
sense-treated cells by =40%. However, nifedipine had no
effect in cells treated with alD antisense ODNs. Notably, the
PTH-induced rise of [Ca2+], in control and sense ODN-treated
cells in the presence of nifedipine was similar in magnitude to
that in alD antisense ODN-treated cells in the presence or
absence of nifedipine. Thus, the inhibitory effects of nifedipine
and alD antisense ODNs were similar in magnitude and not
additive. These results demonstrate that the antisense ODNs
and nifedipine inhibit the same component of the PTH-
induced rise of [Ca2+]1, that attributable to the Ca2+ channel
alD isoform.
The failure of the antisense ODNs to the als or aic Ca2+
channel isoforms to inhibit the PTH-induced rise of [Ca2+l]
could potentially result from their failure to block the expres-
sion of their respective channel proteins. To rule out this
possibility Bay K 8644, an L-type Ca2+ channel agonist, was
used to stimulate channel activity directly. The rise of [Ca2+I
induced by Bay K 8644 was compared in control cells and cells
treated with antisense and sense ODNs to each of the three











FIG. 4. Effect of nifedipine on the PTH-induced rise of intracel-
lular calcium. A[Ca2+Ji, the difference between resting and stimulated
levels of [Ca2+]j after treatment with 10-8 M PTH. In some experi-
ments, nifedipine (NIF, 10 ,uM) was present. In control cells, the basal
level of [Ca2+]i was 124 ± 2 nM and the PTH-stimulated level was 280
± 12 nM (n = 6). *, P < 0.05, control PTH + NIF vs. control PTH;
t, P < 0.05, antisense PTH vs. control PTH; **, P < 0.01, sense PTH
+ NIF vs. sense PTH.
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ODNs significantly reduced the magnitude of the Bay K
8644-induced rise of [Ca2+]i, whereas the corresponding sense
ODNs had no effect. These results provide functional evidence
that the als, aic, and alD antisense ODNs are effective
inhibitors of Ca2+ channel gene expression.
DISCUSSION
Previous studies of Ca2+ channels in osteoblast-like cells (6, 7,
9, 11, 26) and normal rat osteoblasts (9, 12, 27) utilized
electrophysiological techniques to provide evidence for the
presence of L-type channels. However, it has not been clear
whether more than one type of channel was present or what its
relationship was to the Ca2> channels described in excitable
cells. In the present study, three a1 subunit isoforms of L-type
voltage-gated Ca2+ channels were found in UMR-106 osteo-
blast-like osteosarcoma cells. Each of these ai subunit tran-
scripts (ais, acl, and a1D) exhibits a specific pattern of
alternative splicing in the fourth domain involving two adja-
cent regions. The first region is the IVS3 transmembrane
domain in which mutually exclusive alternate exons can be
used, as has been described in several different tissues includ-
ing brain, heart, and aorta (for alc) and in brain (for aID) (17,
21, 28, 29). In each of these tissues both types of exons are
expressed. However, in UMR-106 cells only one of the two
types of exons was found, and it is the same type in each of the
three Ca2+ channel transcripts.
The second region of alternative splicing is in the IVS3-S4
extracellular linker, wherein a deletion may result from exon
skipping or the use of alternate splice acceptor sites. The
presence of a deletion in this region has been found only rarely
(25, 30, 31). This deletion was found to occur in the alc isoform
at a low frequency (<12%) in many tissues (32). However, all
of the Ca2+ channel a, subunit clones isolated from UMR-106
cells contained a deletion in this region. The combination of
the specific IVS3 type found in UMR-106 cells and the
deletion in the S3-S4 linker has been designated variant type
b by Perez-Reyes et al. (30). Our results suggest that UMR-106
osteosarcoma cells express predominantly or exclusively the b
variants of the als, aLc, and alD transcripts.
The functional effects and physiological roles for the two
alternative splicing events that occur in the fourth domain are
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FIG. 5. Effect of calcium channel ODNs on the Bay K 8644-
induced rise of intracellular calcium. A[Ca2+]i, the difference between
resting and stimulated levels of [Ca2+]i after treatment with (S)-(-)-
Bay K 8644 (10 ,uM). In control cells, the basal level of [Ca2+]i was 122
± 2 nM and the Bay K 8644-stimulated level was 232 ± 12 nM. The
results are presented as the percent of the A[Ca2+]1 obtained with
control cells in the same set of experiments (n = 7). *, P < 0.05
antisense vs. sense; **, P < 0.01 antisense vs. sense.
the three different Ca>2 channel a, subunit genes suggests the
involvement of common cis- and/or transacting factors that
regulate the mechanism of splicing. Splicing in this region may
be responsible for similar functional effects in each of the Ca>2
channel proteins. Additional tissue-specific processing of the
UMR-106 als and alD transcripts is likely to occur since the
size of the major transcript (4.8 kb) is significantly smaller than
that reported from other sources (17, 22, 23). The nature of this
difference is presently unknown. For the a1s isoform, the
existence of variants that have an internal deletion has been
reported (24, 33). The present results, however, indicate that
the osteosarcoma transcripts are not formed in a manner
analogous to that described by Malouf et al. (24).
Treatment of osteoblasts with PTH causes a rise of [Ca2+]
that involves both Ca2+ release from intracellular stores and
Ca2+ influx through L-type Ca2+ channels (4-6). In the present
study, inhibition of specific Ca>2 channel isoforms with anti-
sense ODNs was used to demonstrate that PTH selectively
activates the aiD isoform to cause Ca2+ uptake into UMR-106
cells. After exposure of cells to aiD antisense ODNs, the
PTH-induced rise of [Ca2+]1 was inhibited by 64% (Table 1).
A similar reduction in the PTH-induced rise of [Ca2+], was
obtained with nifedipine (Fig. 4) or upon removal of extra-
cellular Ca2+. Thus, the residual rise of [Ca2+]i in cells treated
with aiD antisense ODNs is likely to be due to the mobilization
of Ca>2 from intracellular stores. Antisense ODNs to the als
and alc isoforms had no effect on the PTH-induced rise of
[Ca2+], (Table 1). In addition, the observation that nifedipine
caused no further reduction in the PTH-induced rise of [Ca2+]i
in aiD antisense-treated cells (Fig. 4) supports the conclusion
that the alD isoform is the only L-type Ca2+ channel activated
by PTH. However, Yamaguchi and coworkers (4, 34, 35)
suggested that PTH sequentially activates two distinct Ca>2
channels in UMR-106 cells that appear to be regulated sepa-
rately by second messenger systems involving either cAMP or
protein kinase C. Although the present study provides evi-
dence for activation of only one type of Ca2+ channel al
subunit (a1D) by PTH, it is possible that functional differences
may arise from alternatively spliced isoforms of alD or from
the association of aiD with multiple isoforms of accessory
subunits (,B). Finally, the alD antisense ODNs had no effect on
PTH-induced synthesis of cAMP. These results emphasize the
specificity of the inhibitory effect of the antisense ODNs and
show that other PTH actions are not impaired.
Antisense ODNs directed to each of the three al-subunit
isoforms inhibited the rise of [Ca2+] induced by Bay K 8644
(Fig. 5). These results provide independent confirmation of
the inhibitory effect of the alD antisense ODNs on Ca>2
channel activity. In addition, they demonstrate that the anti-
sense ODNs to the als and alc isoforms effectively inhibit
Ca2+ channel activity. Thus, the lack of an effect of the als and
alc antisense ODNs on PTH-induced Ca>2 uptake does not
result from their failure to block expression of the channel
proteins. It might be expected that the inhibitory effects of the
three different antisense ODNs on the Bay K 8644-induced
rise of [Ca2+]1 would be additive. However, each of antisense
ODNs inhibited -45% of the rise of [Ca>21i, and the inhibition
was not significantly increased by the combination of all three
ODNs (Fig. 5). These results suggest that cooperative inter-
actions may occur between the different Ca2+ channel iso-
forms during activation by Bay K 8644, possibly involving
protein-protein interactions or modulation by [Ca]2+i.
PTH acts on bone cells in a complex and as yet poorly
understood manner that may cause anabolic or catabolic
effects (36). The cellular response to PTH is likely to involve
the interplay between Ca2+ and cAMP second messenger
systems and the precise roles of these two systems remain to be
dissected. Modifications of [Ca>]i may regulate gene tran-
scription from specific promoters that contain Ca2+
responsive elements. Recent studies demonstrate that in-
Biochemistry: Barry et al.
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creases of [Ca2+]i after activation of L-type Ca2+ channels
regulate c-fos gene transcription in neuronal cells (37, 38) and
that c-fos is an important modulator of osteoblast proliferation
and differentiation (39, 40). Interestingly, an increase of
[Ca2+], in UMR-106 cells antagonizes the antiproliferative
effect of cAMP, suggesting a role for Ca2+ in the regulation of
cell growth (34). Aside from PTH, 1,25-(OH)2-vitamin D3,
mechanical stress, estradiol, and testosterone cause rapid Ca2+
influx into osteoblasts through plasma membrane Ca2+ chan-
nels (5, 10, 26, 41-44). The modulation of Ca2+ channel
activity in osteoblasts by many factors that regulate bone
metabolism suggests an important role for the Ca2+ signaling
pathway in bone physiology.
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